DBV Technologies S.A. (DBVT) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, DBV Technologies reported revenue of $5.6M, up 35.8% from $4.2M the year before. Net income was -$146.9M (a -2607.3% net margin), or -$1.05 per diluted share. Operating margin was -2609.2%. Operating activities generated -$121.2M of cash, leaving -$121.7M of free cash flow. At fiscal year end, DBV Technologies held $233.7M in total assets against $64.9M in total liabilities, including $194.2M of cash and equivalents.
Open the full interactive DBV Technologies financials → Quarterly statements, key ratios, valuation history and price charts.
DBV Technologies Key Stats
| Share Price | $9.03 |
|---|---|
| Market Cap | $783.0M |
| Revenue YoY Growth | +35.8% |
| 52-Week Range | $9.03 – $24.54 |
| Shares Outstanding | 433.5 million (basic, 2026 Q2) |
DBV Technologies Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $11.3M | $5.7M | $4.8M | $15.7M | $4.2M | $5.6M |
| Operating Income | -$158.8M | -$98.6M | -$96.6M | -$76.4M | -$116.6M | -$147.1M |
| Pre-Tax Income | -$159.6M | -$98.2M | -$96.2M | -$72.7M | -$113.9M | -$146.5M |
| Income Tax | -$10,000 | -$381,000 | $70,000 | $7,000 | $55,000 | $491,000 |
| Net Income | -$159.6M | -$97.8M | -$96.3M | -$72.7M | -$113.9M | -$146.9M |
| Diluted EPS | -$5.90 | -$3.56 | -$2.48 | -$1.52 | -$1.17 | -$1.05 |
DBV Technologies Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.8M | $644,000 | $900,000 | $700,000 |
| Net Income | -$33.2M | -$44.8M | -$47.6M | -$50.4M |
| Diluted EPS | -$0.24 | -$0.32 | -$0.11 | -$0.12 |
DBV Technologies Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $196.4M | $77.3M | $209.2M | $141.4M | $32.5M | $194.2M |
| Current Assets | $207.4M | $114.4M | $223.1M | $158.9M | $44.4M | $212.9M |
| Total Assets | $272.2M | $146.7M | $246.5M | $183.0M | $65.7M | $233.7M |
| Current Liabilities | $52.7M | $31.4M | $29.5M | $37.3M | $31.1M | $58.0M |
| Total Liabilities | $66.8M | $47.4M | $52.1M | $42.8M | $38.3M | $64.9M |
| Shareholders' Equity | $205.5M | $99.3M | $194.5M | $140.2M | $27.4M | $168.8M |
DBV Technologies Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$165.6M | -$108.2M | -$55.7M | -$79.7M | -$104.5M | -$121.2M |
| Cash From Investing | -$2.9M | -$433,000 | -$100,000 | -$808,000 | -$757,000 | -$1.4M |
| Cash From Financing | $149.5M | $274,000 | $194.1M | $6.8M | $587,000 | $276.2M |
| Free Cash Flow | -$168.3M | -$109.2M | -$56.4M | -$80.3M | -$106.8M | -$121.7M |
Figures from DBV Technologies' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full DBV Technologies financials page for every line item.
DBV Technologies Company Profile
| Ticker | DBVT |
|---|---|
| Exchange | Nasdaq, OTC |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Chatillon |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001613780 |
Frequently Asked Questions
What was DBV Technologies' revenue in fiscal 2025?
DBV Technologies (DBVT) reported revenue of $5.6M for fiscal 2025.
What is DBV Technologies' annual revenue history?
DBV Technologies' annual revenue by fiscal year: 2020: $11.3M; 2021: $5.7M; 2022: $4.8M; 2023: $15.7M; 2024: $4.2M; 2025: $5.6M.
What was DBV Technologies' net income in fiscal 2025?
DBV Technologies reported net income of -$146.9M for fiscal 2025.
What was DBV Technologies' earnings per share (EPS) in fiscal 2025?
DBV Technologies' diluted EPS was -$1.05 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did DBV Technologies generate in fiscal 2025?
DBV Technologies generated -$121.7M of free cash flow in fiscal 2025.
What was DBV Technologies' revenue last quarter?
In its most recent reported quarter (2026 Q2), DBV Technologies reported revenue of $700,000.
How many shares of DBV Technologies are outstanding?
DBV Technologies reported a weighted average of 433.5 million basic shares outstanding in 2026 Q2.
What is DBV Technologies' market cap?
Based on its latest closing price, DBV Technologies (DBVT) has a market capitalization of about $783.0M.
When does DBV Technologies' fiscal year end?
DBV Technologies' fiscal year end, as registered with the SEC, is December 31.
Where is DBV Technologies headquartered?
DBV Technologies lists its business address in Chatillon in its SEC filings.
DBV Technologies Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →